- Home
- RLYB vs THAR Comparison
RLYB vs THAR Comparison
Compare RLYB & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- THAR
- Stock Information
- Founded
- RLYB 2018
- THAR 2017
- Country
- RLYB United States
- THAR United States
- Employees
- RLYB N/A
- THAR N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- THAR Health Care
- Exchange
- RLYB Nasdaq
- THAR Nasdaq
- Market Cap
- RLYB 24.1M
- THAR 22.8M
- IPO Year
- RLYB 2021
- THAR 2022
- Fundamental
- Price
- RLYB $0.61
- THAR $3.10
- Analyst Decision
- RLYB Hold
- THAR Strong Buy
- Analyst Count
- RLYB 2
- THAR 1
- Target Price
- RLYB N/A
- THAR $17.00
- AVG Volume (30 Days)
- RLYB 290.8K
- THAR 276.1K
- Earning Date
- RLYB 11-07-2025
- THAR 11-07-2025
- Dividend Yield
- RLYB N/A
- THAR N/A
- EPS Growth
- RLYB N/A
- THAR N/A
- EPS
- RLYB N/A
- THAR N/A
- Revenue
- RLYB $761,000.00
- THAR N/A
- Revenue This Year
- RLYB N/A
- THAR N/A
- Revenue Next Year
- RLYB N/A
- THAR N/A
- P/E Ratio
- RLYB N/A
- THAR N/A
- Revenue Growth
- RLYB 154.51
- THAR N/A
- 52 Week Low
- RLYB $0.22
- THAR $0.95
- 52 Week High
- RLYB $1.24
- THAR $9.08
- Technical
- Relative Strength Index (RSI)
- RLYB 61.83
- THAR 52.96
- Support Level
- RLYB $0.54
- THAR $2.68
- Resistance Level
- RLYB $0.57
- THAR $3.18
- Average True Range (ATR)
- RLYB 0.04
- THAR 0.29
- MACD
- RLYB 0.01
- THAR 0.01
- Stochastic Oscillator
- RLYB 93.92
- THAR 60.90
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.